|
1
|
Sankaranarayanan R and Ferlay J: Worldwide
burden of gynaecological cancer: The size of the problem. Best
Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar
|
|
2
|
Masoumi Moghaddam S, Amini A, Morris DL
and Pourgholami MH: Significance of vascular endothelial growth
factor in growth and peritoneal dissemination of ovarian cancer.
Cancer Metastasis Rev. 31:143–162. 2012. View Article : Google Scholar :
|
|
3
|
Muñoz-Casares FC, Rufián S, Arjona-Sánchez
Á, Rubio MJ, Díaz R, Casado Á, Naranjo Á, Díaz-Iglesias CJ, Ortega
R, Muñoz-Villanueva MC, et al: Neoadjuvant intraperitoneal
chemotherapy with paclitaxel for the radical surgical treatment of
peritoneal carcinomatosis in ovarian cancer: A prospective pilot
study. Cancer Chemother Pharmacol. 68:267–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan JK, Tian C, Monk BJ, Herzog T, Kapp
DS, Bell J and Young RC; Gynecologic Oncology Group: Prognostic
factors for high-risk early-stage epithelial ovarian cancer: A
Gynecologic Oncology Group study. Cancer. 112:2202–2210. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis
compared to other epithelial cell types? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al Cancer
Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar
|
|
8
|
Havrilesky L, Darcy M, Hamdan H, Priore
RL, Leon J, Bell J and Berchuck A; Gynecologic Oncology Group
Study: Prognostic significance of p53 mutation and p53
overexpression in advanced epithelial ovarian cancer: A Gynecologic
Oncology Group Study. J Clin Oncol. 21:3814–3825. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Risch HA, McLaughlin JR, Cole DE, Rosen B,
Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, et al: Population
BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A
kin-cohort study in Ontario, Canada. J Natl Cancer Inst.
98:1694–1706. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang HJ, Chun SM, Kim KR, Sohn I and Sung
CO: Clinical relevance of gain-of-function mutations of p53 in
high-grade serous ovarian carcinoma. PLoS One. 8:e726092013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giaccia AJ and Kastan MB: The complexity
of p53 modulation: Emerging patterns from divergent signals. Genes
Dev. 12:2973–2983. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Agostino S, Strano S, Emiliozzi V,
Zerbini V, Mottolese M, Sacchi A, Blandino G and Piaggio G: Gain of
function of mutant p53: The mutant p53/NF-Y protein complex reveals
an aberrant transcriptional mechanism of cell cycle regulation.
Cancer Cell. 10:191–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blandino G, Levine AJ and Oren M: Mutant
p53 gain of function: Differential effects of different p53 mutants
on resistance of cultured cells to chemotherapy. Oncogene.
18:477–485. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong P, Karaayvaz M, Jia N, Kaneuchi M,
Hamada J, Watari H, Sudo S, Ju J and Sakuragi N: Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene. 32:3286–3295. 2013.
View Article : Google Scholar :
|
|
15
|
Høgdall EV, Kjaer SK, Blaakaer J,
Christensen L, Glud E, Vuust J and Høgdall CK: P53 mutations in
tissue from Danish ovarian cancer patients: From the Danish
'MALOVA' ovarian cancer study. Gynecol Oncol. 100:76–82. 2006.
View Article : Google Scholar
|
|
16
|
Concin N, Hofstetter G, Berger A,
Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L,
Heim K, et al: Clinical relevance of dominant-negative p73 isoforms
for responsiveness to chemotherapy and survival in ovarian cancer:
Evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res.
11:8372–8383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Helland A, Holm R, Skomedal H,
Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL and Kristensen
GB: TP53 mutations in early-stage ovarian carcinoma, relation to
long-term survival. Br J Cancer. 90:678–685. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ueno Y, Enomoto T, Otsuki Y, Sugita N,
Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, et
al: Prognostic significance of p53 mutation in suboptimally
resected advanced ovarian carcinoma treated with the combination
chemotherapy of paclitaxel and carboplatin. Cancer Lett.
241:289–300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartel F, Jung J, Böhnke A, Gradhand E,
Zeng K, Thomssen C and Hauptmann S: Both germ line and somatic
genetics of the p53 pathway affect ovarian cancer incidence and
survival. Clin Cancer Res. 14:89–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng X, Zhang MQ, Conserva F, Hosny G,
Selivanova G, Bykov VJ, Arnér ES and Wiman KG:
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and
converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis.
4:e8812013. View Article : Google Scholar
|
|
21
|
Issaeva N, Bozko P, Enge M, Protopopova M,
Verhoef LG, Masucci M, Pramanik A and Selivanova G: Small molecule
RITA binds to p53, blocks p53-HDM-2 interaction and activates p53
function in tumors. Nat Med. 10:1321–1328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Russo D, Ottaggio L, Penna I, Foggetti G,
Fronza G, Inga A and Menichini P: PRIMA-1 cytotoxicity correlates
with nucleolar localization and degradation of mutant p53 in breast
cancer cells. Biochem Biophys Res Commun. 402:345–350. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roh JL, Kang SK, Minn I, Califano JA,
Sidransky D and Koch WM: p53-Reactivating small molecules induce
apoptosis and enhance chemotherapeutic cytotoxicity in head and
neck squamous cell carcinoma. Oral Oncol. 47:8–15. 2011. View Article : Google Scholar :
|
|
24
|
Lehmann S, Bykov VJ, Ali D, Andrén O,
Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A,
et al: Targeting p53 in vivo: A first-in-human study with
p53-targeting compound APR-246 in refractory hematologic
malignancies and prostate cancer. J Clin Oncol. 30:3633–3639. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Misawa T, Kikkawa F, Maeda O, Obata NH,
Higashide K, Suganuma N and Tomoda Y: Establishment and
characterization of acquired resistance to platinum anticancer
drugs in human ovarian carcinoma cells. Jpn J Cancer Res. 86:88–94.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
27
|
Kapitanović S, Cacev T, Antica M, Kralj M,
Cavrić G, Pavelić K and Spaventi R: Effect of indomethacin on
E-cadherin and beta-catenin expression in HT-29 colon cancer cells.
Exp Mol Pathol. 80:91–96. 2006. View Article : Google Scholar
|
|
28
|
Sugiyama K, Kajiyama H, Shibata K, Yuan H,
Kikkawa F and Senga T: Expression of the miR200 family of microRNAs
in mesothelial cells suppresses the dissemination of ovarian cancer
cells. Mol Cancer Ther. 13:2081–2091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakahara T, Iwase A, Nakamura T, Kondo M,
Bayasula, Kobayashi H, Takikawa S, Manabe S, Goto M, Kotani T, et
al: Sphingosine-1-phosphate inhibits
H2O2-induced granulosa cell apoptosis via the
PI3K/Akt signaling pathway. Fertil Steril. 98:1001.e1–1008.e1.
2012.
|
|
30
|
Lambert JM, Gorzov P, Veprintsev DB,
Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman
KG and Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding
to the core domain. Cancer Cell. 15:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Utsumi F, Kajiyama H, Nakamura K, Tanaka
H, Mizuno M, Ishikawa K, Kondo H, Kano H, Hori M and Kikkawa F:
Effect of indirect nonequilibrium atmospheric pressure plasma on
anti-proliferative activity against chronic chemo-resistant ovarian
cancer cells in vitro and in vivo. PLoS One. 8:e815762013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duan Z, Choy E and Hornicek FJ: NSC23925,
identified in a high-throughput cell-based screen, reverses
multidrug resistance. PLoS One. 4:e74152009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bykov VJ, Zache N, Stridh H, Westman J,
Bergman J, Selivanova G and Wiman KG: PRIMA-1(MET) synergizes with
cisplatin to induce tumor cell apoptosis. Oncogene. 24:3484–3491.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Supiot S, Zhao H, Wiman K, Hill RP and
Bristow RG: PRIMA-1(met) radiosensitizes prostate cancer cells
independent of their MTp53-status. Radiother Oncol. 86:407–411.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ali D, Jönsson-Videsäter K, Deneberg S,
Bengtzén S, Nahi H, Paul C and Lehmann S: APR-246 exhibits
anti-leukemic activity and synergism with conventional
chemotherapeutic drugs in acute myeloid leukemia cells. Eur J
Haematol. 86:206–215. 2011. View Article : Google Scholar
|
|
36
|
Nahi H, Lehmann S, Mollgard L, Bengtzen S,
Selivanova G, Wiman KG, Paul C and Merup M: Effects of PRIMA-1 on
chronic lymphocytic leukaemia cells with and without hemizygous p53
deletion. Br J Haematol. 127:285–291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mohell N, Alfredsson J, Fransson Å,
Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U
and Wiman KG: APR-246 overcomes resistance to cisplatin and
doxorubicin in ovarian cancer cells. Cell Death Dis. 6:e17942015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zandi R, Selivanova G, Christensen CL,
Gerds TA, Willumsen BM and Poulsen HS:
PRIMA-1Met/APR-246 induces apoptosis and tumor growth
delay in small cell lung cancer expressing mutant p53. Clin Cancer
Res. 17:2830–2841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Izetti P, Hautefeuille A, Abujamra AL, de
Farias CB, Giacomazzi J, Alemar B, Lenz G, Roesler R, Schwartsmann
G, Osvaldt AB, et al: PRIMA-1, a mutant p53 reactivator, induces
apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic
cancer cell lines. Invest New Drugs. 32:783–794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tessoulin B, Descamps G, Moreau P, Maïga
S, Lodé L, Godon C, Marionneau-Lambot S, Oullier T, Le Gouill S,
Amiot M, et al: PRIMA-1Met induces myeloma cell death
independent of p53 by impairing the GSH/ROS balance. Blood.
124:1626–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Russo D, Ottaggio L, Foggetti G, Masini M,
Masiello P, Fronza G and Menichini P: PRIMA-1 induces autophagy in
cancer cells carrying mutant or wild type p53. Biochim Biophys
Acta. 1833:1904–1913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aryee DN, Niedan S, Ban J, Schwentner R,
Muehlbacher K, Kauer M, Kofler R and Kovar H: Variability in
functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing
sarcoma. Br J Cancer. 109:2696–2704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tong L, Chuang CC, Wu S and Zuo L:
Reactive oxygen species in redox cancer therapy. Cancer Lett.
367:18–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Landry WD and Cotter TG: ROS signalling,
NADPH oxidases and cancer. Biochem Soc Trans. 42:934–938. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bailey HH, Mulcahy RT, Tutsch KD,
Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and
Spriggs DR: Phase I clinical trial of intravenous L-buthionine
sulfoximine and melphalan: An attempt at modulation of glutathione.
J Clin Oncol. 12:194–205. 1994.PubMed/NCBI
|
|
46
|
Cox AG, Peskin AV, Paton LN, Winterbourn
CC and Hampton MB: Redox potential and peroxide reactivity of human
peroxiredoxin 3. Biochemistry. 48:6495–6501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cunniff B, Wozniak AN, Sweeney P, DeCosta
K and Heintz NH: Peroxiredoxin 3 levels regulate a mitochondrial
redox setpoint in malignant mesothelioma cells. Redox Biol.
3:79–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim
HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, et al: FOXM1-induced
PRX3 regulates stemness and survival of colon cancer cells via
maintenance of mitochondrial function. Gastroenterology.
149:1006.e9–1016.e9. 2015. View Article : Google Scholar
|
|
49
|
Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji
Y, He Y, Kondo T and Fan J: Decreased selenium-binding protein 1
enhances glutathione peroxidase 1 activity and downregulates HIF-1α
to promote hepatocellular carcinoma invasiveness. Clin Cancer Res.
18:3042–3053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gan X, Chen B, Shen Z, Liu Y, Li H, Xie X,
Xu X, Li H, Huang Z and Chen J: High GPX1 expression promotes
esophageal squamous cell carcinoma invasion, migration,
proliferation and cisplatin-resistance but can be reduced by
vitamin D. Int J Clin Exp Med. 7:2530–2540. 2014.PubMed/NCBI
|
